Perrigo Company plc announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Onexton® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%). Perrigo previously settled litigation with Valeant Pharmaceuticals North America LLC and Dow Pharmaceutical Sciences Inc. for this product. Onexton® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%) is a prescription medicine indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.